Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Down 35.9% in December

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totalling 5,640,000 shares, a decline of 35.9% from the December 15th total of 8,800,000 shares. Based on an average trading volume of 2,360,000 shares, the short-interest ratio is presently 2.4 days.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC grew its position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) by 17.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 278,496 shares of the company's stock after buying an additional 42,376 shares during the quarter. Geode Capital Management LLC owned 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent quarter. Institutional investors and hedge funds own 63.18% of the company's stock.

Reviva Pharmaceuticals Price Performance

Shares of RVPH stock traded down $0.33 during midday trading on Tuesday, reaching $1.58. 3,309,697 shares of the company traded hands, compared to its average volume of 3,447,877. The firm's 50 day simple moving average is $1.59 and its two-hundred day simple moving average is $1.30. The firm has a market cap of $52.84 million, a PE ratio of -1.42 and a beta of -0.12. Reviva Pharmaceuticals has a 1-year low of $0.60 and a 1-year high of $4.83.

Wall Street Analyst Weigh In

RVPH has been the subject of several analyst reports. Roth Capital raised shares of Reviva Pharmaceuticals to a "strong-buy" rating in a report on Friday. Maxim Group raised Reviva Pharmaceuticals from a "hold" rating to a "buy" rating and set a $7.00 price target for the company in a report on Friday. Roth Mkm started coverage on Reviva Pharmaceuticals in a research note on Friday. They issued a "buy" rating and a $7.00 price target on the stock. Finally, EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a "strong-buy" rating in a research report on Monday, September 23rd. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $11.25.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.